drugset / Trial / NCT00630474

Nasal Decongestion and Obstructive Sleep Apnea

NCT00630474

Phase 4 Completed 12 enrolled University of Zurich
RandomizedCrossoverTriple-blindTreatment

Summary

Whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. Therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that decongests the nasal mucosa when applied locally, with placebo in terms of sleep and nocturnal breathing and daytime performance.

Timeline

Start
2004-01
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Xylometazoline Small molecule 0.1 % Intranasal
Comparator Xylometazoline Small molecule 0.15 mg Intranasal